Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

Citius Pharmaceuticals reported its first revenue of $3.9 million in Q1 2026 following the December 2025 launch of LYMPHIR by its majority-owned subsidiary Citius Oncology. The drug, approved for treating relapsed or refractory cutaneous T-cell lymphoma, has begun initial sales through a nationwide distributor network. The company raised $20.9 million in equity financing and is advancing late-stage pipeline candidates Mino-Lok and Halo-Lido while exploring international expansion and combination therapy opportunities.

02/13/2026, 8:00 AM • Benzinga

Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

Citius Oncology reported its first revenue of $3.9 million following the successful December 2025 U.S. commercial launch of LYMPHIR, an FDA-approved immunotherapy for cutaneous T-cell lymphoma. The company established nationwide distribution infrastructure and deployed an AI-enabled commercial platform. Despite positive commercial progress, the company reported a net loss of $5.5 million for Q1 2026 and held $7.3 million in cash as of December 31, 2025.

02/13/2026, 8:00 AM • Benzinga

Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

Citius Oncology closed a registered direct offering and private placement, raising approximately $18 million to support the commercial launch of LYMPHIR and for general corporate purposes.

12/10/2025, 4:30 PM • Benzinga

Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

Citius Oncology raised $18 million through a registered direct offering and private placement to support the commercial launch of LYMPHIR, a novel cancer immunotherapy for cutaneous T-cell lymphoma, with H.C. Wainwright & Co. acting as the exclusive placement agent.

12/09/2025, 8:30 AM • Benzinga

Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

Citius Oncology closed a $9.0 million registered direct offering and private placement, issuing 5,142,858 shares of common stock and accompanying warrants at $1.75 per share, with warrants exercisable at $1.84 per share.

09/10/2025, 4:30 PM • Benzinga

Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

Citius Oncology has entered a securities purchase agreement to sell 5,142,858 shares of common stock at $1.75 per share, with concurrent warrants, expected to raise approximately $9.0 million.

09/09/2025, 8:30 AM • Benzinga

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update

Citius Pharmaceuticals reported its Q3 2025 financial results, highlighting $12.5 million in gross financings and preparations for LYMPHIR's U.S. launch in Q4 2025. The company experienced a reduced net loss compared to the previous year and continues to advance its oncology and critical care product pipeline.

08/12/2025, 4:30 PM • Benzinga

Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update

Citius Oncology reported its Q3 2025 financial results, highlighting preparations for the commercial launch of LYMPHIR, a therapy for cutaneous T-cell lymphoma, with $12.5 million raised to support pre-launch initiatives.

08/12/2025, 4:30 PM • Benzinga

Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators

Pharmaceutical companies are advancing treatments for rare diseases, with Soligenix leading efforts in developing HyBryte, a promising therapy for cutaneous T-cell lymphoma (CTCL), a rare skin cancer affecting older adults.

08/06/2025, 8:30 AM • Benzinga

Citius Oncology Announces Pricing of $9.0 Million Public Offering

Citius Oncology priced a public offering of 6,818,182 shares and warrants at $1.32 per share, expecting to raise approximately $9.0 million to support LYMPHIR commercialization and general corporate purposes.

07/16/2025, 9:15 AM • Benzinga

Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention

Cancer research companies are attracting investor interest as the oncology market is projected to grow significantly, with several firms showing promising clinical trial results and strategic developments in cancer treatments.

07/08/2025, 10:25 AM • Benzinga

The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

Analysts forecast the global oncology drug market to exceed $900 billion by 2034, with biotech firms like Oncolytics, Teva, Citius, ADC Therapeutics, and OS Therapies driving cancer treatment innovation amid potential NCI funding cuts.

06/26/2025, 11:44 AM • Benzinga